GSK se­cures an­oth­er ex-Chi­na ADC deal with Han­soh Phar­ma with $185M up­front

The year of an­ti­body-drug con­ju­gates isn’t done yet, as GSK is adding an­oth­er li­cens­ing part­ner­ship with Han­soh Phar­ma for an­oth­er ADC with an up­front pay­ment of $185 mil­lion. There is al­so up to $1.525 bil­lion in mile­stone pay­ments in store for Han­soh, ac­cord­ing to a Hong Kong Stock Ex­change fil­ing.

In Oc­to­ber, the com­pa­nies an­nounced that GSK will li­cense an ADC from Han­soh, named HS-20089, with an $85 mil­lion up­front and a fur­ther $1.48 bil­lion in mile­stone pay­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER